Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-prostatic Neuraxial Block with Lidocaine and Ethanol in Prostate Cancer
NCT06703437Phase 1Active, not recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Dec 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ethanol in prostate cancer (PCa), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: Dose-Limiting Toxicity at 2 weeks and Maximally Tolerated Dose at 2 weeks. Started Dec 2022; status: active, not recruiting.
02
Drugs
ethanol
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06703437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06703437.